Cardiff Oncology, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Services » Medical Or Nursing Services
NTRANatera, Inc. 2.10%114.521.1%$129.28m
GHGuardant Health, Inc. -0.32%109.800.0%$83.00m
DVADaVita, Inc. 1.10%120.323.7%$73.05m
NVTAInvitae Corp. -0.36%27.981.2%$67.71m
FLGTFulgent Genetics, Inc. 0.36%92.250.6%$62.73m
AMEDAmedisys, Inc. 2.02%260.6211.4%$59.93m
OSHOak Street Health, Inc. 0.32%63.080.0%$48.72m
CHEChemed Corp. 1.20%476.4510.1%$48.65m
SDCSmileDirectClub, Inc. 0.57%7.060.0%$34.57m
LHCGLHC Group, Inc. 1.34%215.182.9%$31.94m
NEONeoGenomics, Inc. 0.88%46.105.2%$26.89m
ONEM1Life Healthcare, Inc. 0.11%27.040.0%$26.61m
ACHCAcadia Healthcare Co., Inc. 0.08%61.7226.9%$21.49m
CANOCano Health, Inc. 0.09%10.730.0%$19.00m
OPCHOption Care Health, Inc. -0.29%20.720.0%$13.59m

Company Profile

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.